Improving Transparency in Decision Models: Current Issues and Potential Solutions

PharmacoEconomics
Volume 37, Issue 11, November 2019
https://link.springer.com/journal/40273/37/11

 

Themed Issue : Improving Transparency in Decision Models
Editorial
Improving Transparency in Decision Models: Current Issues and Potential Solutions
Paul Tappenden, J. Jaime Caro
Decision-analytic models have become an essential tool used to inform health technology assessments (HTAs). These models provide a mathematical framework to synthesize data from various sources to support predictions of the economic and health impact of new and existing health technologies. They tend to be complex and are rarely fully validated against external data; yet, use of their forecasts requires trust in their accuracy and lack of bias. Thus, decision makers and other stakeholders want to be able to review their structure, inputs, and assumptions fully, and this necessitates that these models be available and transparent enough to permit adequate review. While most would agree that model transparency is a highly desirable goal, the drive towards its achievement has led to concerns with the disincentives, potential loss of control, harmed intellectual property rights, and additional efforts demanded. In this special issue of PharmacoEconomics we have gathered an impressive and diverse collection of papers addressing many aspects of this important topic in our field…

Cost-consequence analysis of influenza vaccination among the staff of a large teaching hospital in Rome, Italy: A pilot study

PLoS One
http://www.plosone.org/
[Accessed 16 Nov 2019]

 

Research Article
Cost-consequence analysis of influenza vaccination among the staff of a large teaching hospital in Rome, Italy: A pilot study
Vittoria Colamesta, Andrea Tamburrano, Andrea Barbara, Andrea Gentili, Daniele Ignazio La Milia, Filippo Berloco, Americo Cicchetti, Daniele Piacentini, Roberta Galluzzi, Sergio Riccardo Mastrodonato, Andrea Cambieri, Walter Ricciardi, Patrizia Laurenti
Research Article | published 14 Nov 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0225326

CRISPR/Cas9 gene editing in the West Nile Virus vector, Culex quinquefasciatus Say

PLoS One
http://www.plosone.org/
[Accessed 16 Nov 2019]

 

CRISPR/Cas9 gene editing in the West Nile Virus vector, Culex quinquefasciatus Say
Michelle E. Anderson, Jessica Mavica, Lewis Shackleford, Ilona Flis, Sophia Fochler, Sanjay Basu, Luke Alphey
Research Article | published 12 Nov 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0224857
Abstract
Culex quinquefasciatus Say is an opportunistic blood feeder with a wide geographic distribution which is also a major vector for a range of diseases of both animals and humans. CRISPR/Cas technologies have been applied to a wide variety of organisms for both applied and basic research purposes. CRISPR/Cas methods open new possibilities for genetic research in non-model organisms of public health importance. In this work we have adapted microinjection techniques commonly used in other mosquito species to Culex quinquefasciatus, and have shown these to be effective at generating homozygous knock-out mutations of a target gene in one generation. This is the first description of the kmo gene and mutant phenotype in this species.

Association between numeracy and self-rated poor health in 33 high- and upper middle- income countries

Preventive Medicine
Volume 127 October 2019
https://www.sciencedirect.com/journal/preventive-medicine/vol/127/suppl/C

 

Research article Abstract only
Association between numeracy and self-rated poor health in 33 high- and upper middle- income countries
Justin Rodgers, Sujay Kakarmath, Vanessa Denis, Marta Encinas-Martin, S.V. Subramanian
Article 105872
Highlights
:: Numeracy is inversely correlated with poor self-rated health.
:: Associations are robust to adjustment for literacy, education, and sociodemographic factors.
:: Low levels of general literacy may exacerbate the numeracy-health relationship.
:: The numeracy-self-rated health relationship varies by gender, education, and across countries.
:: Interventions aimed at improving both numeracy and literacy may yield greater improvements in population health.

Impact of mandatory law on vaccine hesitancy spectrum: The case of measles vaccine catch-up activities in Tuscany, Italy

Vaccine
Volume 37, Issue 49 Pages 7201-7288 (20 November 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/49

 

Discussion No access
Impact of mandatory law on vaccine hesitancy spectrum: The case of measles vaccine catch-up activities in Tuscany, Italy
L. Tavoschi, F. Quattrone, E. De Vita, P.L. Lopalco
Pages 7201-7202

Exploring indirect protection associated with influenza immunization – A systematic review of the literature

Vaccine
Volume 37, Issue 49 Pages 7201-7288 (20 November 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/49

 

Review article Open access
Exploring indirect protection associated with influenza immunization – A systematic review of the literature
Lindsay Friedman, Ariane Renaud, Delaney Hines, Anne Winter, … Bryna F. Warshawsky
Pages 7213-7232

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 16 Nov 2019
[No new, unique, relevant content]

 

BBC
http://www.bbc.co.uk/
Accessed 16 Nov 2019
[No new, unique, relevant content]

 

The Economist
http://www.economist.com/
Accessed 16 Nov 2019
[No new, unique, relevant content]

 

Financial Times
http://www.ft.com/home/uk
Accessed 16 Nov 2019
[No new, unique, relevant content]

 

Forbes
http://www.forbes.com/
Accessed 16 Nov 2019
[No new, unique, relevant content]

 

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 16 Nov 2019
[No new, unique, relevant content]

Foreign Policy
http://foreignpolicy.com/
Accessed 16 Nov 2019
Argument
The Real Reason to Panic About China’s Plague Outbreak
It’s not the disease that’s worrisome—it’s the Chinese government’s response to it.
By Laurie Garrett
| November 16, 2019, 1:44 AM
The Chinese government’s response to this month’s outbreak of plague has been marked by temerity and some fear, which history suggests is entirely appropriate. But not all fear is the same, and Beijing seems to be afraid of the wrong things. Rather than being concerned about the germs and their spread, the government seems mostly motivated by a desire to manage public reaction about the disease. Those efforts, however, have failed—and the public’s response is now veering toward a sort of plague-inspired panic that’s not at all justified by the facts…

 

The Guardian
http://www.guardiannews.com/
Accessed 16 Nov 2019
Germany
German parliament approves compulsory measles vaccinations
Bundestag backs law that will fine parents up to €2,500 if children are not inoculated
Germany’s parliament has voted to make measles vaccinations compulsory for children, in response to a global rise in cases of the disease.
Parents who refuse to get their children inoculated face fines of up to €2,500 (£2,140) and a likely ban from nursery or school.
The measles protection act will come into force next March, and its introduction is likely to be watched closely by advocates of mandatory immunisation in other countries, including Britain.
The UK health secretary, Matt Hancock, said in September the government was “looking very seriously” at making vaccinations compulsory for state school pupils.
The Bundestag approved the law on Thursday after months of debate, with doctors speaking out both in favour of and against the legislation…

 

New Yorker
http://www.newyorker.com/
Accessed 16 Nov 2019
[No new, unique, relevant content]

 

New York Times
http://www.nytimes.com/
Accessed 16 Nov 2019
Asia Pacific
Former Deputy Head of China’s Drug Regulator Sentenced to 16 Years in Prison
Wu Zhen, a former deputy head of China’s food and drug regulator, was sentenced to 16 years in prison by a Chinese court, state television reported on Friday.
By Reuters Nov. 15

Business
As Swine Fever Fries China Vaccine Sales, Boehringer Rewrites Prescription for Recovery
Germany’s Boehringer Ingelheim, the global No. 2 in animal health, is having to rebuild itself in China after a deadly pig disease decimated sales of unrelated mainstay vaccines, bringing write-offs and leaving it facing a three-year slog to recovery.
By Reuters Nov. 14

 

Washington Post
https://www.washingtonpost.com/
Accessed 16 Nov 2019
[No new, unique, relevant content]

Think Tanks et al

Think Tanks et al

Brookings
http://www.brookings.edu/
Accessed 16 Nov 2019
[No new relevant content]

 

Center for Global Development
http://www.cgdev.org/page/press-center
Accessed 16 Nov 2019
[No new relevant content]

 

CSIS
https://www.csis.org/
Accessed 16 Nov 2019
[No new relevant content]

 

Council on Foreign Relations
http://www.cfr.org/
Accessed 16 Nov 2019
[No new relevant content]

 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=pre ss-release
[No new relevant content]

Vaccines and Global Health: The Week in Review :: 9 November 2019

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_9 Nov 2019

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure :: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents :: Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany

Milestones :: Perspectives :: Research

 

Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure
November 06, 2019
− New England Journal of Medicine publishes primary endpoint analysis from ongoing Phase 3 study of Takeda’s dengue vaccine candidate
− Over 20,000 study participants in dengue-endemic areas in Latin America and Asia received two doses of Takeda’s dengue vaccine candidate or placebo administered three months apart
− Results demonstrated overall vaccine efficacy of 80.2% (12-month follow-up after second dose) against virologically confirmed dengue; exploratory analyses of secondary endpoints showed 82.2% vaccine efficacy among baseline seropositives and 74.9% vaccine efficacy among baseline seronegatives; the vaccine candidate was generally well tolerated with no important safety risks observed to date
− Formal assessment of secondary efficacy endpoints (18-month follow-up after second dose) will be presented later this year; safety and efficacy will be assessed over a total of four and a half years

… “The results of this first analysis are very encouraging, indicating that the vaccine could potentially provide important public health benefits against dengue fever and hospitalization,” said Humberto Reynales, M.D., Ph.D., a lead author of the New England Journal of Medicine paper. “It will be important to further analyze the trial results over time in order to assess the long-term efficacy and safety of the vaccine. If longer follow-up data confirm this initial observation, we are looking at a significant step forward in the global fight against dengue.”

“According to the World Health Organization, dengue represents one of the ten biggest global health threats, and it is critical that we have access to a safe and effective vaccine candidate that can reduce the devastating impact dengue fever has in endemic regions,” said In-Kyu Yoon, M.D., Senior Advisor, International Vaccine Institute. “Historically, vaccine development against dengue has been challenging, especially for people who haven’t previously been exposed to dengue, and these results demonstrate protection from dengue fever, including among many participants without prior dengue.”…

 

::::::

New England Journal of Medicine
November 6, 2019
DOI: 10.1056/NEJMoa1903869
Original Article Free Preview
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
Shibadas Biswal, M.D., Humberto Reynales, M.D., Ph.D., Xavier Saez-Llorens, M.D., Pio Lopez, M.D., Charissa Borja-Tabora, M.D., Pope Kosalaraksa, M.D., Chukiat Sirivichayakul, M.D., Veerachai Watanaveeradej, M.D., Luis Rivera, M.D., Felix Espinoza, M.D., LakKumar Fernando, M.D., Reynaldo Dietze, M.D., Kleber Luz, M.D., Rivaldo Venâncio da Cunha, M.D., José Jimeno, M.D., Eduardo López-Medina, M.D., Astrid Borkowski, M.D., Ph.D., Manja Brose, M.Sc., Martina Rauscher, Ph.D., Inge LeFevre, M.D., Svetlana Bizjajeva, Ph.D., Lulu Bravo, M.D., and Derek Wallace, M.B., B.S. for the TIDES Study Group*
Abstract
Background
Dengue, a mosquito-borne viral disease, was designated a World Health Organization top 10 threat to global health in 2019.
Methods
We present primary efficacy data from part 1 of an ongoing phase 3 randomized trial of a tetravalent dengue vaccine candidate (TAK-003) in regions of Asia and Latin America in which the disease is endemic. Healthy children and adolescents 4 to 16 years of age were randomly assigned in a 2:1 ratio (stratified according to age category and region) to receive two doses of vaccine or placebo 3 months apart. Participants presenting with febrile illness were tested for virologically confirmed dengue by serotype-specific reverse-transcriptase polymerase chain reaction. The primary end point was overall vaccine efficacy in preventing virologically confirmed dengue caused by any dengue virus serotype.
Results
Of the 20,071 participants who were given at least one dose of vaccine or placebo (safety population), 19,021 (94.8%) received both injections and were included in the per-protocol analysis. The overall vaccine efficacy in the safety population was 80.9% (95% confidence interval [CI], 75.2 to 85.3; 78 cases per 13,380 [0.5 per 100 person-years] in the vaccine group vs. 199 cases per 6687 [2.5 per 100 person-years] in the placebo group). In the per-protocol analyses, vaccine efficacy was 80.2% (95% CI, 73.3 to 85.3; 61 cases of virologically confirmed dengue in the vaccine group vs. 149 cases in the placebo group), with 95.4% efficacy against dengue leading to hospitalization (95% CI, 88.4 to 98.2; 5 hospitalizations in the vaccine group vs. 53 hospitalizations in the placebo group). Planned exploratory analyses involving the 27.7% of the per-protocol population that was seronegative at baseline showed vaccine efficacy of 74.9% (95% CI, 57.0 to 85.4; 20 cases of virologically confirmed dengue in the vaccine group vs. 39 cases in the placebo group). Efficacy trends varied according to serotype. The incidence of serious adverse events was similar in the vaccine group and placebo group (3.1% and 3.8%, respectively).
Conclusions
TAK-003 was efficacious against symptomatic dengue in countries in which the disease is endemic. (Funded by Takeda Vaccines; TIDES ClinicalTrials.gov number, NCT02747927. opens in new tab.)

 

::::::

Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany
− The manufacturing plant opening marks an important milestone for Takeda’s mission to tackle the global threat of dengue
− The site will be utilized for formulation, fill, finish and secondary packaging of Takeda’s dengue vaccine candidate
− Takeda’s dengue vaccine candidate is currently being evaluated in the pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial1
November 05, 2019
SINGEN, Germany–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited today announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003. The Singen vaccine plant will be utilized for formulation, fill, finish and secondary packaging of the dengue vaccine candidate starting with the packaging line. Takeda invested more than 130 million Euro and will employ up to 200 employees in the vaccine plant…

Nine African countries agree to begin journey towards pooled procurement to increase their access to affordable life-saving vaccines

Milestones :: Perspectives :: Research

 

Nine African countries agree to begin journey towards pooled procurement to increase their access to affordable life-saving vaccines
Brazzaville, 6 November 2019 – Nine middle-income countries in Africa have agreed to work towards pooled procurement mechanisms by first sharing vital information on their vaccine purchasing practices, including the prices they pay and their suppliers. Sharing information and ultimately pooling their orders will better leverage their individual purchasing power and thus strengthen their vaccine security and increase their access to affordable life-saving vaccines.

Their commitment on 1 November to improve in-country and cross-border processes was made following a three-day workshop organized by the World Health Organization (WHO) Regional Office for Africa in Mbabane, Kingdom of Eswatini to address access to safe and affordable vaccines in middle-income countries, where immunization coverage is decreasing.

The workshop brought together the countries that, due to their middle-income status, are not eligible for immunization financing support from Gavi, the Vaccine Alliance (Algeria, Botswana, Cabo Verde, Kingdom of Eswatini, Gabon, Mauritius, Namibia, São Tomé and Príncipe and Seychelles). Participants included officials from the respective health and finance ministries, procurement officials, immunization officers and members of national regulatory authorities for vaccines and medicines.

Despite progress in reducing morbidity and mortality due to vaccine-preventable diseases, around 8.5 million children living in the WHO African Region still do not receive all the basic and necessary vaccines. With many middle-income countries in the region transitioning from donor-supported to domestically funded immunization programmes, access to vaccines remains a challenge due to limited financial resources and to obstacles in accessing a timely and affordable vaccine supply.

A shift towards more strategic approaches to vaccine procurement is critical to improve access to affordable vaccines for middle-income countries in the African Region.

The nine countries agreed on activities to be conducted in common that will work towards a pooled procurement process in the future. These activities include coordinating joint market research, sharing vaccine supplier information and monitoring vaccine prices. By coordinating the informed buying of vaccines, these countries will have greater stability in their vaccine supply as well as increased bargaining power for lower prices.

Five of the countries, those in the regional organization of Small Island Developing States, have already created a single purchasing bloc, which was highlighted during the workshop as an innovative model due to its ability to leverage a better negotiating position and thus achieve reduced prices. Pooling demand can be particularly beneficial to countries with small populations that combine their orders to improve their negotiation terms with suppliers.
Pooled procurement also contributes towards strengthening existing specialized skills for national vaccine procurement and allows for continuous stability in vaccine supply.

The country representatives agreed on collaborating with different models of group purchasing, with all committing to share information and some agreeing to work towards joint price negotiating.

“Pooling vaccine procurement is a major step towards increasing immunization coverage in these countries and the African Region as a whole,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “We must work together to improve vaccine delivery so that all children are protected from preventable diseases. I am heartened to see such strong cooperation between countries to make universal immunization coverage a reality.”…

Johnson & Johnson Announces Submission of European Marketing Authorisation Applications for Janssen’s Investigational Ebola Vaccine Regimen

Milestones :: Perspectives :: Research

 

Johnson & Johnson Announces Submission of European Marketing Authorisation Applications for Janssen’s Investigational Ebola Vaccine Regimen
Data from multiple preclinical, Phase 1, 2 and 3 studies support applications, which have been granted Accelerated Assessment by European Medicines Agency
November 07, 2019
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have submitted Marketing Authorisation Applications (MAAs) to the European Medicines Agency (EMA) seeking licensure for an investigational Ebola vaccine regimen for the prevention of Ebola Virus Disease (EVD) caused by Zaire ebolavirus species. Two MAAs have been submitted in parallel supporting each vaccine in the two-dose regimen (Ad26.ZEBOV, MVA-BN-Filo). In September 2019, the EMA’s Committee for Medicinal Products for Human Use (CHMP) granted an Accelerated Assessment for these applications.

“It is vital that we ensure global preparedness for Ebola given that the world’s largest Ebola outbreaks have taken place in the last six years alone, with the latest currently underway in the Democratic Republic of the Congo (DRC),” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson. “With an understanding that vaccines have an important role to play in countering this epidemic threat, we look forward to the EMA’s review of our applications for licensure.”

The vaccine regimen includes Ad26.ZEBOV as the first dose, which is based on Janssen’s AdVac® technology, and MVA-BN-Filo as the second dose, which is based on Bavarian Nordic’s MVA-BN® technology and is administered approximately eight weeks later. The MAAs are supported by data from Phase 1, 2 and 3 clinical studies evaluating the safety and immunogenicity of the vaccine regimen in adults and children1-7, preclinical studies, and immunobridging analyses. To date, more than 6,500 volunteers across the U.S., Europe and Africa have participated in over 10 clinical studies of the Janssen vaccine.

“Our goal is to deliver a vaccine that can be used both in response to Ebola outbreaks, and also more proactively as a prophylactic tool to help countries protect their populations,” said Johan Van Hoof, M.D., Global Therapeutic Area Head, Vaccines, and Managing Director, Janssen Vaccines & Prevention B.V., Janssen Pharmaceutica N.V. “We are grateful to our many global partners who have helped us reach this important stage of development.”…

Emergencies

Emergencies

Ebola – DRC+
Public Health Emergency of International Concern (PHEIC)

Ebola Outbreak in DRC 66: 05 November 2019
1. Situation update
In the past week, from 28 October to 3 November 2019, 10 new confirmed Ebola virus disease (EVD) cases were reported from five health zones in two affected provinces in the Democratic Republic of the Congo. Though the number of new confirmed EVD cases reported is lower this week, compared to the 20 cases reported last week, security issues and poor access continue to slow response activities in certain health zones. This can prevent the detection of cases in these hard to reach areas.
Violence this week in Lwemba Health Area in the Mandima Health Zone, caused the death of an Ebola response community health worker, and left his spouse critically injured with multiple wounds. WHO and partners condemned the attack, adding that acts of violence against individuals involved with the response are unacceptable and compromise the ability of health workers to provide assistance to communities impacted by the devastating effects of Ebola…

Implementation of ring vaccination protocol
As of 3 November 2019, 246,824 people at risk have consented to and received the rVSV-ZEBOV-GP Ebola Vaccine with 2,865 vaccinated in the past week

::::::
::::::

POLIO
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 06 November 2019
:: The GPEI is pleased to announce that the UK Government has confirmed its commitment to eradicating polio by pledging a £400 million contribution for the next four years, which will help vaccinate more than 400 million children a year. Read more on the remarkable announcement.
:: In Pakistan, a circulating vaccine-derived poliovirus type 2 has been confirmed.  A detailed investigation into the origin of the outbreak is ongoing, with circulation confirmed in a geographically-limited area, and outbreak response is being planned and implemented.
:: Are you an immunization expert interested in serving on the Strategic Advisory Group of Experts (SAGE) on polio? The call for nominations for membership on the working group has now been issued, targeting individuals to submit their nominations.
: Want to know the future of polio eradication efforts in Africa? Then stay tuned for a Facebook live interview with Dr Pascal Mkanda, chief polio expert in the WHO African Region, on 08 November 2019 at 10:00am, West Africa Time.

Summary of new viruses this week (AFP cases and ES positives):
:: Afghanistan— one WPV1 case and one WPV1 positive environmental sample;
:: Pakistan— three WPV1 cases and 19 WPV1-positive environmental samples;
:: Angola— 7 cVDPV2 cases and one cVDPV2 positive environmental sample;
:: Central African Republic— one cVDPV2 case and one cVDPV2 positive environmental sample;
:: Cote d’Ivoire one cVDPV2 positive environmental sample;
:: Ghana two cVDPV2 cases;
:: Philippines— one cVDPV2 case and four cVDPV2 positive environmental samples.

::::::

UK aid to help vaccinate more than 400 million children a year against polio
Press release Published 5 November 2019
International Development Secretary Alok Sharma has pledged new UK aid support to help vaccinate more than 400 million children a year against polio.
:: UK support will help vaccinate more than 750 children a minute against polio in developing countries around the world
:: The UK package of up to £400 million will help support 20 million health workers and volunteers
:: Polio was wiped out in UK in the 1980s, but three countries – Pakistan, Afghanistan and Nigeria – are still not officially wild polio free

::::::

Editor’s Note:
WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.

WHO Grade 3 Emergencies [to 9 Nov 2019]

Democratic Republic of the Congo
:: Ebola Outbreak in DRC 66: 05 November 2019

Mozambique floods – No new digest announcements identified
Nigeria – No new digest announcements identified
Somalia – No new digest announcements identified
South Sudan – No new digest announcements identified
Syrian Arab Republic – No new digest announcements identified
Yemen – No new digest announcements identified

::::::

WHO Grade 2 Emergencies [to 9 Nov 2019]

Sudan
:: Yellow fever campaign launches in Khartoum State as final phase of countrywide immunization drive 7 November 2019
:: WHO scales up cholera vigilance in Khartoum, Sudan 5 November 2019

Afghanistan – No new digest announcements identified
Angola – No new digest announcements identified
Burkina Faso [in French] – No new digest announcements identified
Burundi – No new digest announcements identified
Cameroon – No new digest announcements identified
Central African Republic – No new digest announcements identified
Ethiopia – No new digest announcements identified
HIV in Pakistan – No new digest announcements identified
Iran floods 2019 – No new digest announcements identified
Iraq – No new digest announcements identified
Libya – No new digest announcements identified
Malawi floods – No new digest announcements identified
Measles in Europe – No new digest announcements identified
MERS-CoV – No new digest announcements identified
Myanmar – No new digest announcements identified
Niger – No new digest announcements identified
occupied Palestinian territory – No new digest announcements identified
Ukraine – No new digest announcements identified
Zimbabwe – No new digest announcements identified

 

::::::

WHO Grade 1 Emergencies [to 9 Nov 2019]

Chad – No new digest announcements identified
Djibouti – No new digest announcements identified
Kenya – No new digest announcements identified
Mali – No new digest announcements identified
Namibia – viral hepatitis – No new digest announcements identified
Tanzania – No new digest announcements identified

::::::
::::::

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic
:: Syria ǀ Flash Update #11, Humanitarian impact of the military operation in north-eastern Syria, 29 – 31 October 2019 [EN/AR]

Yemen – No new digest announcements identified

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Editor’s Note:
Ebola in the DRC has bene added as a OCHA “Corporate Emergency” this week:
CYCLONE IDAI and Kenneth
:: 08 Nov 2019 South Sudan: CERF allocates up to $15 million for flooding response

EBOLA OUTBREAK IN THE DRC – No new digest announcements identified

::::::
::::::

WHO & Regional Offices [to 9 Nov 2019]

WHO & Regional Offices [to 9 Nov 2019]

8 November 2019 News release
WHO aids flood-hit populations across Africa and the Eastern Mediterranean Region
Well over a million people have been affected in some of the worst-hit countries of Benin, Cameroon, Central African Republic, Somalia, South Sudan and Yemen.

 

::::::

Weekly Epidemiological Record, 8 November 2019, vol. 94, 45 (pp. 513–524)
:: Elimination of human onchocerciasis: progress report, 2018–2019

 

::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Nine African countries agree to begin journey towards pooled procurement to increase their access to affordable life-saving vaccines 06 November 2019
[See Milestones above for detail]

WHO Region of the Americas PAHO
:: Municipalities from Brazil, Guatemala, and Honduras receive the 2019 PAHO Malaria Champions Award (11/06/2019)
:: Improving adolescent health in the Caribbean (11/06/2019)
:: Guyana launches mass drug administration campaign to intensify efforts to end Lymphatic Filariasis (11/06/2019)

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
No new digest content identified.

WHO Eastern Mediterranean Region EMRO
:: ECHO and WHO partnership meets critical trauma needs in Yemen 6 November 2019
:: WHO scales up cholera vigilance in Khartoum, Sudan 5 November 2019

WHO Western Pacific Region
No new digest content identified.

Announcements

Announcements

 

Paul G. Allen Frontiers Group [to 9 Nov 2019]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
Press Release
The Paul G. Allen Frontiers Group Names New Allen Distinguished Investigators
November 6, 2019
Five new awardees will embark on stem cell and tissue research with the potential to impact human health”
Samantha Morris, Ph.D.
Washington University in St. Louis
Joshua Rabinowitz, Ph.D.
Princeton University
Clive Svendsen, Ph.D.
Cedars-Sinai
Savas Tay, Ph.D.
University of Chicago
James Wells, Ph.D.
Cincinnati Children’s Hospital Medical Center

 

BMGF – Gates Foundation [to 9 Nov 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.

 

Bill & Melinda Gates Medical Research Institute [to 9 Nov 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

 

CARB-X [to 9 Nov 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
11.06.2019  |
CARB-X funds Techulon to support the development of innovative nano therapeutics capable of killing drug-resistant bacteria by precisely targeting essential genes
Techulon project is the 50th project funded by CARB-X since it was launched in 2016
(BOSTON, MA)  – CARB-X is awarding Techulon Inc., located in the Virginia Tech Corporate Research Center in Blacksburg, VA, USA, up to $785,000 in non-dilutive funding to develop a new class of antimicrobial that would kill drug-resistant bacteria by targeting specific genes critical to the bacteria’s survival. The CARB-X award supports preclinical hit-to-lead development of Techulon’s drug candidates targeting Acinetobacter baumannii and Pseudomonas aeruginosa, two superbugs that have been identified by the World Health Organization (WHO) as ‘priority pathogens’ posing the greatest threat to global health and by the US Centers for Disease Control and Prevention (CDC) as ‘serious threats’ to human health.
The Techulon project is the 50th innovative antibacterial early development project funded by CARB-X, established in July 2016. To date, CARB-X has invested more than $150 million in non-dilutive funding to accelerate the development of antibiotics, vaccines, diagnostics and other life-saving products to address drug-resistant bacteria, with additional funds committed if projects achieve certain milestones. The CARB-X portfolio has 31 active projects in five countries…

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 9 Nov 2019]
http://cepi.net/
No new digest content identified.

 

Clinton Health Access Initiative, Inc. (CHAI) [to 9 Nov 2019]
https://clintonhealthaccess.org/about/
News & Press Releases
No new digest content identified.

 

EDCTP [to 9 Nov 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.

 

Emory Vaccine Center [to 9 Nov 2019]
http://www.vaccines.emory.edu/
No new digest content identified.

 

European Medicines Agency [to 9 Nov 2019]
http://www.ema.europa.eu/ema/
News & Press Releases
No new digest content identified.

 

European Vaccine Initiative [to 9 Nov 2019]
http://www.euvaccine.eu/news-events
No new digest content identified.

 

FDA [to 9 Nov 2019]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements
November 8, 2019 – FDA approves first therapy to treat patients with rare blood disorder
Today the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions…

November 6, 2019 – Statement on the agency’s efforts to protect patients through postmarket drug safety surveillance practices
… The Cures Act included a new requirement that the FDA make our best practices for drug safety surveillance publicly available on the web. Following the passage of the Cures Act we posted a statement announcing the risk-based principles we use for postmarket safety surveillance. Today, we’re announcing the availability of our draft document, “Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff,” which expands upon those principles. This draft best practice document outlines our approach for timely postmarket analyses of drugs and biologics, and includes a high-level overview of tools, methods, and signal detection and evaluation activities, using varied data sources, for drug safety surveillance to provide a broader context and a general overview of our overarching effort and commitment in this area….

 

Fondation Merieux [to 9 Nov 2019]
http://www.fondation-merieux.org/
News, Events
December 3 – 4, 2019 – Geneva (Switzerland)
Mérieux Foundation co-organized event
6th GTFCC Working Group on Oral Cholera Vaccine

20 – 22 Jan 2020
Mérieux Foundation co-organized event
Dengue pre-vaccination screening strategies workshop
Les Pensières Center for Global Health, Veyrier-du-Lac (France)

 

Gavi [to 9 Nov 2019]
https://www.gavi.org/
Latest news
05 November 2019
Democratic Republic of Congo launches major push against measles, cholera, and rotavirus
Measles follow-up immunisation campaign, emergency oral cholera vaccine campaign, and rotavirus vaccine introduction to protect millions against combination of epidemics.

 

GHIT Fund [to 9 Nov 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

 

Global Fund [to 9 Nov 2019]
https://www.theglobalfund.org/en/news/
News & Stories
Funding Model
Updated Documents and Technical Guidance for Applicants
08 November 2019
Updated resources for applicants are now available on the Global Fund website in preparation for the 2020-2022 funding period.

These documents have been updated:
:: Funding requests forms and instructions on the Funding Request Applications page
:: Programmatic gap tables on the Funding Request Applications page
:: Funding Landscape Table download in English | Español | Français
:: Modular Framework Handbook download in English | Español | Français

Applicants can familiarize themselves with the following core technical investment documents:
:: HIV Information Note download in English | Español | Français
:: Tuberculosis Information Note download in English | Español | Français
:: Malaria Information Note download in English | Español | Français
:: Building Resilient and Sustainable Systems for Health through Global Fund Investments Information Note download in English | Español | Français

 

Hilleman Laboratories [to 9 Nov 2019]
http://www.hillemanlabs.org/
No new digest content identified.

 

Human Vaccines Project [to 9 Nov 2019]
http://www.humanvaccinesproject.org/media/press-releases/
Press Releases
No new digest content identified.

 

IAVI [to 9 Nov 2019]
https://www.iavi.org/newsroom
No new digest content identified.

 

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

 

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
No new digest content identified.

 

 

IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.

 

IFRC [to 9 Nov 2019]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Mozambique
Mozambique: Thousands at risk of disease and malnutrition as rainy season begins
Beira/Geneva, 8 November 2019—More than half a year since cyclones Idai and Kenneth hit Mozambique, thousands of people are at risk of disease outbreaks and worsening food insecurity during the coming rainy season.  Food insecurity is expected to affec …
8 November 2019

Asia Pacific
Philippines: Thousands in need of humanitarian assistance after Mindanao earthquakes
More than 180,000 people are affected with many families requiring humanitarian assistance after a series of powerful earthquakes, struck Cotabato province in Mindanao, Philippines.
5 November 2019

 

IVAC [to 9 Nov 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates
10 Years of Progress in Global Immunization Programs Celebration
The International Vaccine Access Center (IVAC) will be celebrating its 10th anniversary on December 9, 2019 with an event at the Johns Hopkins Bloomberg School of Public Health featuring Executive Director Dr. Bill Moss, Senior Advisor Mathu Santosham, and a keynote address by Dr. Orin Levine, Director of Global Delivery Programs at the Bill and Melinda Gates Foundation and the original founder of IVAC. Comments by Dr. Kate O’Brien, IVAC’s immediate past Executive Director and current Director of Immunization, Vaccines and
Biologicals at the World Health Organization, will open the event.

 

IVI [to 9 Nov 2019]
http://www.ivi.int/
Selected IVI News & Announcements
IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety
Institute expected to increase contributions to vaccine development activities worldwide
November 1, 2019

 

JEE Alliance [to 9 Nov 2019]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

MSF/Médecins Sans Frontières [to 9 Nov 2019]
http://www.msf.org/
Latest [Selected Announcements]
Honduras
More than 5,000 patients treated during MSF respons…
Project Update 8 Nov 2019

DRC Ebola outbreaks
Crisis update – November 2019
Crisis Update 5 Nov 2019

Sudan
Four questions on the malaria outbreak in western Sudan
Interview 4 Nov 2019

 

National Vaccine Program Office – U.S. HHS [to 9 Nov 2019]
https://www.hhs.gov/vaccines/about/index.html
NVAC 2020 Meetings
February 13-14, 2020 NVAC Meeting
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)

 

NIH [to 9 Nov 2019]
http://www.nih.gov/news-events/news-releases
Selected News Releases
Study vaccine protects monkeys against four types of hemorrhagic fever viruses
November 8, 2019 — The vaccine provided protection from Ebola virus, Sudan virus, Marburg virus and Lassa virus.

 

PATH [to 9 Nov 2019]
https://www.path.org/media-center/
Selected Announcements
November 7, 2019 by PATH
Blood pressure check with your manicure?
Communities for Healthy Hearts in Vietnam uses local volunteers and businesses to help people with hypertension discover their condition and take steps to manage it

 

Sabin Vaccine Institute [to 9 Nov 2019]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

 

UNAIDS [to 9 Nov 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
7 November 2019
Confronting the link between HIV and gender-based violence in Jamaica

5 November 2019
Worldwide, more than half of new HIV infections now among key populations and their sexual partners
… Key populations make up a small proportion of the general population, but they are at extremely high risk of acquiring HIV infection. Available data suggest that the risk of HIV acquisition among gay men and other men who have sex with men was 22 times higher in 2018 than it was among all adult men. Similarly, the risk of acquiring HIV for people who inject drugs was 22 times higher than for people who do not inject drugs, 21 times higher for sex workers than adults aged 15–49 years and 12 times higher for transgender women than adults aged 15–49 years….

 

UNICEF [to 9 Nov 2019]
https://www.unicef.org/media/press-releases
Selected Statements, Press Releases, Reports
Press release
60,000 young refugees and migrants who arrived in Italy alone need ongoing support as they transition to adulthood – UN Agencies
Key challenges include discrimination, difficulty finding work, administrative bottlenecks and lack of legal information
08/11/2019

Press release
200,000 children affected as heavy flooding in Somalia brings increased risk of malnutrition and disease outbreak
UNICEF and partners working to meet urgent needs of most vulnerable children
05/11/2019

 

Vaccination Acceptance Research Network (VARN) [to 9 Nov 2019]
https://vaccineacceptance.org/news.html#header1-2r
No new digest content identified.

 

Vaccine Confidence Project [to 9 Nov 2019]
http://www.vaccineconfidence.org/
No new digest content identified.

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 9 Nov 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

 

Wellcome Trust [to 9 Nov 2019]
https://wellcome.ac.uk/news
News | 8 November 2019
We are carbon off-setting our travel

Twitter | 7 November 2019
A new science for epidemics must include these 7 disciplines (opens in a new tab)

Opinion | 5 November 2019
It’s time to rethink the way we talk about one of the most urgent threats to our health
by Jeremy Farrar
Tackling big health challenges is dependent on science and innovation, but also on the public understanding and engaging with them.

Opinion | 4 November 2019
7 things manifesto writers should know about science
by Martin Smith

 

The Wistar Institute [to 9 Nov 2019]
https://www.wistar.org/news/press-releases
Press Release Nov. 8, 2019
Synthetic DNA Technology Applied as a Novel Strategy for Delivery of Anti-HIV Antibodies
Synthetic DNA-encoded monoclonal antibodies (DMAbs) allow for in vivo production of broadly neutralizing antibodies in preclinical studies.

 

World Organisation for Animal Health (OIE) [to 9 Nov 2019]
http://www.oie.int/en/for-the-media/press-releases/2019/
27/09/19
‘United Against Rabies’ collaboration celebrates one year of progress towards zero human rabies deaths by 2030
Since the launch of ‘Zero by 30’ in 2018, the United Against Rabies collaboration has made progress to empower, engage and enable countries to reach the rabies elimination goal by 2030. Released today on World Rabies Day, the first annual progress report describes the incremental, collaborative impact of the four partners[1] in promoting the One Health approach[2] and achieving the three objectives of the Global Strategic Plan.

 

 

::::::

 

ARM [Alliance for Regenerative Medicine] [to 9 Nov 2019]
https://alliancerm.org/press-releases/
November 5, 2019
The Alliance for Regenerative Medicine Releases Q3 2019 Sector Report, Highlighting Industry Trends and Metrics
Highlighted findings from the Q3 2019 data report include:
:: Globally, companies active in gene and cell therapies and other regenerative medicines raised nearly $2.6 billion in the third quarter of 2019, bringing the year-to-date total financings to more than $7.4 billion. The report also includes financial data broken out by technology type and financing type.
:: There were 1,052 clinical trials underway worldwide at the close of the third quarter of 2019, with more than 60% of those in oncology and 5% in musculoskeletal disorders and central nervous system disorders. The report also includes figures on clinical trials by phase and indication, as well as by technology type.

 

BIO [to 9 Nov 2019]
https://www.bio.org/insights/press-release
No new digest content identified.

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 9 Nov 2019]
http://www.dcvmn.org/
No new digest content identified.

 

IFPMA [to 9 Nov 2019]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

 

PhRMA [to 9 Nov 2019]
http://www.phrma.org/
Selected Press Releases, Statements
No new digest content identified.

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

A childhood immunization education program for parents delivered during late pregnancy and one-month postpartum: a randomized controlled trial

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content

 

Research article
A childhood immunization education program for parents delivered during late pregnancy and one-month postpartum: a randomized controlled trial
Improved immunization rates have reduced the incidence of vaccine-preventable diseases (VPDs) in advanced nations. Japan’s unique vaccination system classifies vaccines into routine vaccines ostensibly require…
Authors: Hiroko Otsuka-Ono, Narumi Hori, Hiroshi Ohta, Yukari Uemura and Kiyoko Kamibeppu
Citation: BMC Health Services Research 2019 19:798
Published on: 5 November 2019

Health professionals’ acceptance and willingness to pay for hepatitis B virus vaccination in Gondar City Administration governmental health institutions, Northwest Ethiopia

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content

 

Health professionals’ acceptance and willingness to pay for hepatitis B virus vaccination in Gondar City Administration governmental health institutions, Northwest Ethiopia
Hepatitis B virus (HBV) infection is a global public health problem. The burden of the disease is high in low and middle income countries like Ethiopia. However, for highly vulnerable groups such as health pro…
Authors: Siwule Abiye, Mezgebu Yitayal, Giziew Abere and Asefa Adimasu
Citation: BMC Health Services Research 2019 19:796
Content type: Research article
Published on: 5 November 2019

Mumps: MMR vaccination and genetic diversity of mumps virus, 2007–2011 in Catalonia, Spain

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 9 Nov 2019)

 

Research article
Mumps: MMR vaccination and genetic diversity of mumps virus, 2007–2011 in Catalonia, Spain
Mumps is a vaccine-preventable disease but outbreaks have been reported in persons vaccinated with two doses of MMR vaccine.
Authors: Irene Barrabeig, Andrés Antón, Núria Torner, Tomàs Pumarola, Josep Costa and Àngela Domínguez
Citation: BMC Infectious Diseases 2019 19:954
Content type: Research article
Published on: 9 November 2019

What do patients with unmet medical needs want? A qualitative study of patients’ views and experiences with expanded access to unapproved, investigational treatments in the Netherlands

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 9 Nov 2019)

 

What do patients with unmet medical needs want? A qualitative study of patients’ views and experiences with expanded access to unapproved, investigational treatments in the Netherlands
Patients with unmet medical needs sometimes resort to non-standard treatment options, including the use of unapproved, investigational drugs in the context of clinical trials, compassionate use or named-patient programs. The views and experiences of patients with unmet medical needs regarding unapproved, investigational drugs have not yet been examined empirically.
Authors: Eline M. Bunnik and Nikkie Aarts
Content type: Research article
9 November 2019
Open Access

mHealth communication to strengthen postnatal care in rural areas: a systematic review

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 9 Nov 2019)

 

mHealth communication to strengthen postnatal care in rural areas: a systematic review
Postnatal care (PNC) in rural areas is characterised by low uptake, with possible effect on maternal and neonatal mortality rates. Mobile health (mHealth) communication has been proposed to promote the uptake …
Authors: Florence Mbuthia, Marianne Reid and Annali Fichardt
Citation: BMC Pregnancy and Childbirth 2019 19:406
Content type: Research article
Published on: 6 November 2019

Immunity to rubella: an Italian retrospective cohort study

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 9 Nov 2019)

 

Research article
Immunity to rubella: an Italian retrospective cohort study
International guidelines recommend that healthcare workers (HCWs) have presumptive evidence of immunity to rubella and that susceptible HCWs and doubt cases receive two doses of the MMR vaccine. However, a sma…
Authors: Francesco Paolo Bianchi, Sara De Nitto, Pasquale Stefanizzi, Angela Maria Vittoria Larocca, Cinzia Annatea Germinario and Silvio Tafuri
Citation: BMC Public Health 2019 19:1490
Content type: Research article
Published on: 8 November 2019

The fog of genetics: what is known, unknown and unknowable in the genetics of complex traits and diseases

EMBO Reports
Volume 20 Issue 11 5 November 2019
https://www.embopress.org/toc/14693178/current

 

Opinion 21 October 2019
The fog of genetics: what is known, unknown and unknowable in the genetics of complex traits and diseases
João Pedro de Magalhães, Jingwei Wang
A major task for genetics is searching for genetic variants associated with disease. But we may well be missing a large number of “unknown unknown” alleles in the “fog of genetics”.

Preparing scientists for a visual future : Visualization is a powerful tool for research and communication but requires training and support

EMBO Reports
Volume 20 Issue 11 5 November 2019
https://www.embopress.org/toc/14693178/current

 

Science & Society 14 October 2019
Preparing scientists for a visual future : Visualization is a powerful tool for research and communication but requires training and support
Shraddha Nayak. Janet H Iwasa
The increasing complexity of biological data along with the need to communicate results requires visualization. It requires more training and support though to help scientists create efficient visual representations of their work.

Knowing antimicrobial resistance in practice: a multi-country qualitative study with human and animal healthcare professionals

Global Health Action
Volume 12, 2019 Supp 1
https://www.tandfonline.com/toc/zgha20/12/sup1?nav=tocList

 

Article
Knowing antimicrobial resistance in practice: a multi-country qualitative study with human and animal healthcare professionals
Maddy Pearson & Clare Chandler
Article: 1599560
Published online: 11 Jul 2019

A Professional Standard for Informed Consent for Stem Cell Therapies

JAMA
November 5, 2019, Vol 322, No. 17, Pages 1625-1728
http://jama.jamanetwork.com/issue.aspx

 

Viewpoint
A Professional Standard for Informed Consent for Stem Cell Therapies
Jeremy Sugarman, MD, MPH, MA; Roger A. Barker, MRCP, PhD; R. Alta Charo, JD
JAMA. 2019;322(17):1651-1652. doi:10.1001/jama.2019.11290
This Viewpoint summarizes recommendations from an International Society for Stem Cell Research task force charged with developing professional standards of patient consent for stem cell–based interventions offered outside a clinical trial given the spread of unregulated stem cell clinics offering unproven therapies.

Government Role in Regulating Vaccine Misinformation on Social Media Platforms

JAMA Pediatrics
November 2019, Vol 173, No. 11, Pages 1007-1115
http://archpedi.jamanetwork.com/issue.aspx

 

Viewpoint
Government Role in Regulating Vaccine Misinformation on Social Media Platforms
Y. Tony Yang, ScD, LLM, MPH; David A. Broniatowski, PhD; Dorit Rubinstein Reiss, PhD
JAMA Pediatr. 2019;173(11):1011-1012. doi:10.1001/jamapediatrics.2019.2838
This Viewpoint discusses the challenges of balancing free speech against harms caused by vaccine misinformation on social media platforms and what the government’s role could potentially be in combating misinformation.

Prevalence of Immunodeficiency in Children With Invasive Pneumococcal Disease in the Pneumococcal Vaccine EraA Systematic Review

JAMA Pediatrics
November 2019, Vol 173, No. 11, Pages 1007-1115
http://archpedi.jamanetwork.com/issue.aspx

 

Review
Prevalence of Immunodeficiency in Children With Invasive Pneumococcal Disease in the Pneumococcal Vaccine EraA Systematic Review
Coen Butters, BMed, DCH; Linny Kimly Phuong, BPharm(Hons), MBBS, DCH, MPH; Theresa Cole, BM, MRCPCH, PhD, FRACP; et al.
JAMA Pediatr. 2019;173(11):1084-1094. doi:10.1001/jamapediatrics.2019.3203
This systematic review of 17 studies assesses risk of primary immunodeficiency in children presenting with invasive pneumococcal disease with no other predisposing condition.

Public Knowledge of Human Papillomavirus and Receipt of Vaccination Recommendations

JAMA Pediatrics
November 2019, Vol 173, No. 11, Pages 1007-1115
http://archpedi.jamanetwork.com/issue.aspx

 

Research Letter
Public Knowledge of Human Papillomavirus and Receipt of Vaccination Recommendations
Ryan Suk, MS; Jane R. Montealegre, PhD; Gizem S. Nemutlu, PhD; et al.
JAMA Pediatr. 2019;173(11):1099-1102. doi:10.1001/jamapediatrics.2019.3105
This cross-sectional survey study assesses knowledge of human papillomavirus by age and sex.

Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules

Journal of the Pediatric Infectious Diseases Society (JPIDS)
Volume 8, Issue 5, November 2019
https://academic.oup.com/jpids/issue

 

ORIGINAL ARTICLES
Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules
Jennifer C Moïsi, Seydou Yaro, Sita S Kroman, Clarisse Gouem, Dramane Bayane
J Pediatric Infect Dis Soc, Volume 8, Issue 5, November 2019, Pages 422–432, https://doi.org/10.1093/jpids/piy075
PCV13 has a satisfactory reactogenicity and immunogenicity profile when administered to infants, toddlers, and children according to alternative immunization schedules in Burkina Faso.

ICPD at 25 years: time to expand the agenda

The Lancet
Nov 09, 2019 Volume 394 Number 10210 p1685-1778, e35
https://www.thelancet.com/journals/lancet/issue/current

 

Editorial
ICPD at 25 years: time to expand the agenda
The Lancet
In September, 1994, 11 000 delegates from governments, the UN, non-governmental organisations, and media gathered in Cairo, Egypt, for the International Conference on Population and Development (ICPD). This event was transformative for the reproductive health and rights community. The global consensus that emerged in Cairo—manifested in the ICPD Programme of Action adopted by 179 countries—shifted the focus of the development agenda away from demographics towards sexual and reproductive health and wellbeing, individual rights, and gender equality. 25 years on, the community will reconvene in Nairobi, Kenya, on Nov 12–14, to review progress and accelerate the implementation of the ICPD Programme of Action…

Nature at 150: evidence in pursuit of truth

Nature
Volume 575 Issue 7781, 7 November 2019
http://www.nature.com/nature/current_issue.html

 

Editorial | 06 November 2019
Nature at 150: evidence in pursuit of truth
A century and a half has seen momentous changes in science. But evidence and transparency are more important than ever before.
… In other respects, Nature now is just the same as it was at the start. We will continue in our mission to stand up for research, serve the global research community and communicate the results of science around the world. We will strive to hold to account those in positions of responsibility in research, policy and industry, and to continue to advocate for fewer unintended harmful consequences of research for people and the planet.
Research, science, knowledge, scholarship — however we might choose to characterize the marshalling of evidence in the pursuit of truth — the values we hold are more important than ever before.

Immunization: vital progress, unfinished agenda

Nature
Volume 575 Issue 7781, 7 November 2019
http://www.nature.com/nature/current_issue.html

 

Review Article | 06 November 2019
Immunization: vital progress, unfinished agenda
An overview of the effects of vaccines on global morbidity and mortality, vaccine safety issues, and the hurdles involved in proceeding from vaccine discovery to successful implementation.
Peter Piot, Heidi J. Larson[…] & Beate Kampmann
Abstract
Vaccination against infectious diseases has changed the future of the human species, saving millions of lives every year, both children and adults, and providing major benefits to society as a whole. Here we show, however, that national and sub-national coverage of vaccination varies greatly and major unmet needs persist. Although scientific progress opens exciting perspectives in terms of new vaccines, the pathway from discovery to sustainable implementation can be long and difficult, from the financing, development and licensing to programme implementation and public acceptance. Immunization is one of the best investments in health and should remain a priority for research, industry, public health and society.

A new twenty-first century science for effective epidemic response

Nature
Volume 575 Issue 7781, 7 November 2019
http://www.nature.com/nature/current_issue.html

 

Review Article | 06 November 2019
A new twenty-first century science for effective epidemic response
Juliet Bedford, Jeremy Farrar[…] & John Nkengasong
Abstract
With rapidly changing ecology, urbanization, climate change, increased travel and fragile public health systems, epidemics will become more frequent, more complex and harder to prevent and contain. Here we argue that our concept of epidemics must evolve from crisis response during discrete outbreaks to an integrated cycle of preparation, response and recovery. This is an opportunity to combine knowledge and skills from all over the world—especially at-risk and affected communities. Many disciplines need to be integrated, including not only epidemiology but also social sciences, research and development, diplomacy, logistics and crisis management. This requires a new approach to training tomorrow’s leaders in epidemic prevention and response.

PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels

Nature Genetics
Volume 51 Issue 11, November 2019
https://www.nature.com/ng/volumes/51/issues/11

 

Comment | 01 November 2019
PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels
A fundamental problem in rare-disease diagnostics is the lack of consensus as to which genes have sufficient evidence to attribute causation. To address this issue, we have created PanelApp ( https://panelapp.genomicsengland.co.uk ), a publicly available knowledge base of curated virtual gene panels.
Antonio Rueda Martin, Eleanor Williams[…] & Ellen M. McDonagh

A framework for tiered informed consent for health genomic research in Africa

Nature Genetics
Volume 51 Issue 11, November 2019
https://www.nature.com/ng/volumes/51/issues/11

 

Comment | 28 October 2019
A framework for tiered informed consent for health genomic research in Africa
A generic framework for providing participant information and implementing a tiered consent process for health genomic research in Africa can help to harness global health benefits from sharing and meta-analysis of African genomic data while simultaneously respecting and upholding the autonomy and individual choices of African research participants.
Victoria Nembaware, Katherine Johnston[…] & Nicki Tiffin